Abstract 2934: GSK3β modulates chemoresistance in epithelial ovarian cancer by Cutter, Noelle L, Ph.D. & Pathak, Naeha
Molloy College
DigitalCommons@Molloy
Faculty Works: Biology, Chemistry, and
Environmental Studies Biology, Chemistry, and Environmental Science
7-2016
Abstract 2934: GSK3β modulates chemoresistance
in epithelial ovarian cancer
Noelle L. Cutter Ph.D.
Molloy College, ncutter@molloy.edu
Naeha Pathak
Follow this and additional works at: https://digitalcommons.molloy.edu/bces_fac
Part of the Chemistry Commons, and the Oncology Commons
DigitalCommons@Molloy Feedback
This Abstract is brought to you for free and open access by the Biology, Chemistry, and Environmental Science at DigitalCommons@Molloy. It has
been accepted for inclusion in Faculty Works: Biology, Chemistry, and Environmental Studies by an authorized administrator of
DigitalCommons@Molloy. For more information, please contact tochtera@molloy.edu,thasin@molloy.edu.
Recommended Citation
Cutter, Noelle L. Ph.D. and Pathak, Naeha, "Abstract 2934: GSK3β modulates chemoresistance in epithelial ovarian cancer" (2016).
Faculty Works: Biology, Chemistry, and Environmental Studies. 5.
https://digitalcommons.molloy.edu/bces_fac/5
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA 
Abstract 
Introduction: Epithelial ovarian cancer is one of the most common gynecological malignancies and 
the fifth most frequent cause of cancer death in women, affecting over 22,000 women annually. 
Nearly 15,500 affected women die from this disease annually, and chemoresistance from the 
commonly prescribed platinum-based drug, carboplatin, is a major contributor to this mortality. 
Previous studies have identified genes with CpG islands that are methylated and transcriptionally 
silenced in resistant epithelial ovarian cancer patients. One of these genes is GSK3β, an important 
regulator of apoptosis and cell growth in the Wnt pathway. Thus, understanding the role of GSK3β 
suppression in chemoresistance of epithelial ovarian cancer can help contribute to more effective 
treatments for this disease. By performing different assays our study examined the functional role 
that GSK3β plays in carboplatin chemoresistance. 
Procedure: Human ovarian surface epithelium (HOSE) 6-3 cell line was utilized, which is 
characterized as sensitive to carboplatin therapy. The cells were studied in six groups: 1) untreated; 
2) treated with Lithium Chloride (LiCl); 3) treated with carboplatin; 4) treated with carboplatin and 
LiCl; 5) treated with doxorubicin as control; 6) treated with doxorubicin and LiCl as another control. 
LiCl is known to suppress GSK3β gene expression. We took images of cells using a fluorescence 
microscope. We also performed the Neutral Red Dye assay that determines cell viability, Vybrant® 
MTT Cell Assay which measures amount of non-viable cells, Caspase 3 Assay which measures cell 
apoptosis, and we did cell counting using a hemocytometer and a light microscope. Data analysis 
was done by T-tests using Microsoft Excel®, with p < .05 for significance. 
Summary of Data: More growth was observed in the carboplatin and LiCl group compared to the 
carboplatin group alone on microscopy. Neutral Red Dye assay: Compared to the cells exposed to 
carboplatin alone, those exposed to carboplatin and LiCl were more viable (p <0.01). Vybrant® MTT 
Cell Assay: the cells treated with carboplatin and LiCl showed lesser amounts of nonviable cells as 
compared to the carboplatin alone group (p<0.01). Caspase 3 Assay: the cells treated with 
carboplatin and LiCl were less apoptotic, compared to cells treated with carboplatin alone (p <0.01). 
Cell Counting: cells treated with carboplatin and LiCl had significantly more growth compared to the 
cells treated with carboplatin alone (p <0.01). 
Conclusion: Our results show that cells with suppressed GSK3β had increased proliferation and 
reduced apoptosis, strongly suggesting that silenced GSK3β expression contributes to carboplatin 
resistance and GSK3β expression is vital to carboplatin chemosensitivity. Future in vivo studies 
could further investigate the role of GSK3β methylation to facilitate the design of potential genome-
guided treatments for patients with chemoresistant epithelial ovarian cancer. 
 
